Skip to main content

Table 1 Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver

From: Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases

  PATIENT 1 PATIENT 2 PATIENT 3 PATIENT 4
Description of Cases
 Age at SCNECP Diagnosis (years) 74 68 74 76
 CPAC Gleason Grade 3 + 4 = 7 4 + 5 = 9 3 + 4 = 7 4 + 5 = 9
 PSA Level (ng/mL) at CPAC Diagnosis 5.81 50 5.6 68.9
 Average Interval Between CPAC and SCNECP (months) 144 12 168 84
 Liver Biopsy Site NOS Right hepatic lobe NOS Right hepatic lobe
 Average PSA Level (ng/mL) at SCNECP Diagnosis (ref: 0–4) 5.1 0.31 5.12 8.77
 Average CEA Level (ng/mL) at SCNECP Diagnosis (ref: 0–4.7 ng/mL) 52.3 4.8 N/A 28.2
 Average CA19–9 Level (U/mL) at SCNECP Diagnosis (ref: 0–35 U/mL) 18 1048 N/A N/A
 ADT Yes Yes Yes Yes
 Radiation Yes Yes Yes Yes
 Chemotherapy Yes Yes No Yes
 Radical Prostatectomy Yes No Yes No
 Sites of SCNECP Metastasis Liver, rectum, various LN Liver, retroperitoneal LN Liver, adrenal, retroperitoneal LN, bone Liver and bone
 Average Interval Between SCNECP and Death (months) 26 2 0.75 4.5
Pathologic Findings
 Synaptophysin + + + +
 Chromogranin + + + +
 AE1/AE3 + + + +
 Ki-67 >  90% >  90% 80–90% 70–80%
 NKX3.1 Focal +
 TTF-1 + +
 PSA N/A N/A
 PAP N/A N/A +
 ERG + (weak)*
  1. SCNECP small cell neuroendocrine carcinoma of the prostate, CPAC conventional prostate adenocarcinoma, PSA prostate specific antigen, NOS not otherwise specified, CEA carcinoembryoninc antigen, CA19–9 carbohydrate antigen 19–9, ADT androgen deprivation therapy, PAP prostatic acid phosphatase, ERG ETS-related gene
  2. *This case was sent out for molecular analysis and the TMPRSS2-ERG gene fusion was identified